Cipla to Partner with Hetero to Make Anaemia Biosimilar

June 19, 2014

Mumbai-based Cipla said on Thursday it will partner with fellow Indian drugmaker Hetero to launch a biosimilar for the treatment of anaemia caused by chronic kidney disease.

The biosimilar drug, Darbepoetin alfa — sold by Amgen as Aranesp — will be marketed under the brand name Actorise.

Cipla said Actorise will be available in 25 mcg and 40 mcg strength pre-filled syringes.

Darbepoetin alfa, a second generation erythropoietin, requires only once-weekly dosing, as the drug is able to maintain hemoglobin levels for a longer period of time, the company said.
More than 100,000 patients each year need renal replacement therapy, the company said, adding that most will develop anaemia and will need drugs such as Darbepoetin alfa to maintain their hemoglobin and reduce the need for blood transfusions.

Cipla Chief Medical Officer Jaideep Gogtay said the product’s launch reinforces the company’s commitment to expand its biosimilar product pipeline. He added that the company expects more deals across therapy areas in the near future. — Kellen Owings

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.